In this issue:
Allogeneic SCT improves MDS outcomes across high-risk genetic subgroups
Prevalence and significance of DDX41 gene variants
Birtamimab + standard of care in AL amyloidosis
Long-term sutimlimab improves quality of life in cold agglutinin disease
Real-world safety of eculizumab
Younger matched unrelated vs. older sibling SCT donors in B-cell ALL
Post-SCT neurological complications with CNI-free GVHD prophylaxis
Long-term eltrombopag for advanced MDS/AML and severe thrombocytopenia
CAR T-cells for post-SCT relapse of B-cell ALL
Glofitamab in real-world relapsed/refractory DLBCL
Please login below to download this issue (PDF)